Emergent BioSolutions plummets on weak 2026 revenue guidance, Q4 results
Source: SeekingAlpha
2026-02-27 10:32:41 ET
More on Emergent Biosolutions
- Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript
- Emergent BioSolutions Inc. 2025 Q4 - Results - Earnings Call Presentation
- Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Emergent BioSolutions outlines $720M–$760M 2026 revenue target as transformation plan advances
- Emergent BioSolutions authorizes $50 million stock repurchase program
Read the full article on Seeking Alpha
For further details see:
Emergent BioSolutions plummets on weak 2026 revenue guidance, Q4 results
Emergent Biosolutions Inc.
NASDAQ: EBS
EBS Trading
-1.27% G/L:
$8.145 Last:
357,648 Volume:
$8.20 Open:
EBS Latest News
March 03, 2026 08:00:00 am
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
February 26, 2026 04:05:00 pm
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026 04:01:00 pm
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness
February 26, 2026 04:01:00 pm
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
EBS Stock Data
$592,950,394
50,839,325
1.42%
58
N/A
Pharmaceuticals
Healthcare
US
Gaithersburg
